Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.

Prostate cancer and prostatic diseases - 1 Jun 2023

Snaterse Gido, Mies Rosinda, van Weerden Wytske M, French Pim J, Jonker Johan W, Houtsmuller Adriaan B, van Royen Martin E, Visser Jenny A, Hofland Johannes

Abstract excerpt

BACKGROUND: Androgen receptor (AR) ligand-binding domain (LBD) mutations occur in ~20% of all castration-resistant prostate cancer (CRPC) patients. These mutations confer ligand promiscuity, but the affinity for many steroid hormone pathway intermediates is unknown. In this study, we investigated the stimulation of clinically relevant AR-LBD mutants by endogenous and exogenous steroid hormones present in CRPC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucocorticoids

Share to Prednisolone

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Steroids

Share to Testosterone

Source

Identifiers

PMID: 35046557
DOI: 10.1038/s41391-022-00491-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.PMID 35046557Read ↗

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsSemantic proximity Read ↗

Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.Semantic proximity Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.Semantic proximity Read ↗

5β-Dihydrotestosterone and mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Androgen receptor plasticity and its implications for prostate cancer therapy.Semantic proximity Read ↗

Androgen receptor mutations for precision medicine in prostate cancer.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.